LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors

医学 不良事件通用术语标准 急性毒性 放射治疗 毒性 放射科 骨盆 不利影响 腹部 核医学 内科学
作者
Sai Duriseti,James Kavanaugh,Jeffrey J. Szymanski,Yi Huang,Franco Basarabescu,Aadel A. Chaudhuri,Lauren E. Henke,Pamela Parker Samson,Alexander J. Lin,Clifford G. Robinson,Matthew B. Spraker
出处
期刊:Radiotherapy and Oncology [Elsevier BV]
卷期号:167: 317-322 被引量:83
标识
DOI:10.1016/j.radonc.2021.11.023
摘要

Purpose Stereotactic body radiotherapy (SBRT) is an attractive treatment option for patients with metastatic and/or unresectable tumors, however its use is limited to smaller tumors. Lattice is a form of spatially fractionated radiotherapy that may allow safe delivery of ablative doses to bulky tumors. We previously described Lattice SBRT, which delivers 20 Gy in 5 fractions with a simultaneous integrated boost to 66.7 Gy in a defined geometric arrangement (Lattice boost). The goal of this study was to prospectively evaluate the acute toxicity and quality of life (QoL) of patients with large tumors (>5 cm) treated with Lattice SBRT. Methods This was a single-arm phase I trial conducted between October 2019 and August 2020. Patients with tumors > 4.5 cm were eligible. Lattice SBRT was delivered every other day. The primary outcome was the rate of 90-day treatment-associated (probably or definitely attributable) grade 3 + acute toxicity by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 criteria. Other outcomes included changes in patient reported toxicity and QoL inventories, GTV, and peripheral blood cytokines. Results Twenty patients (22 tumors) were enrolled. Median GTV was 579.2 cc (range: 54.2–3713.5 cc) in volume and 11.1 cm (range: 5.6–21.4 cm) in greatest axial diameter. Fifty percent of tumors were in the thorax, 45% abdomen/pelvis, and 5% extremity. There was no likely treatment-associated grade 3 + toxicity in the 90-day period (acute and sub-acute). There was one case of grade 4 toxicity possibly associated with Lattice SBRT. Conclusions This phase I study met its primary endpoint of physician reported short-term safety. An ongoing phase II clinical trial of Lattice SBRT will evaluate late safety and efficacy of this novel technique.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
黄啦啦完成签到,获得积分10
1秒前
Tt发布了新的文献求助10
1秒前
幸运小鱼完成签到,获得积分10
1秒前
zhawenchang发布了新的文献求助10
2秒前
2秒前
Ava的应助被CC采纳,获得10
3秒前
大面包完成签到,获得积分10
3秒前
xxy完成签到,获得积分10
3秒前
上官若男的应助被大白采纳,获得10
4秒前
Owen的应助被可研小菜鸟采纳,获得10
4秒前
5秒前
chi2完成签到,获得积分10
5秒前
5秒前
fangzi完成签到,获得积分10
6秒前
6秒前
6秒前
yeo完成签到,获得积分10
7秒前
落寞的寒云完成签到,获得积分10
7秒前
TEXAS完成签到,获得积分10
7秒前
7秒前
bkagyin的应助被浅陌采纳,获得10
7秒前
7秒前
田様的应助被一叶知秋采纳,获得10
7秒前
陈天降低完成签到,获得积分10
8秒前
8秒前
大水桶发布了新的文献求助10
8秒前
咸鱼打滚完成签到,获得积分10
8秒前
xyc完成签到,获得积分10
10秒前
慕青的应助被鳗鱼水云采纳,获得10
10秒前
10秒前
LCFXR发布了新的文献求助10
11秒前
LL完成签到,获得积分10
11秒前
11秒前
micor发布了新的文献求助10
11秒前
11秒前
11秒前
11秒前
XialianWeng完成签到,获得积分10
12秒前
Hong发布了新的文献求助10
12秒前
zhawenchang发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8154161
求助须知:如何正确求助?哪些是违规求助? 9550701
关于积分的说明 21700590
捐赠科研通 7743260
什么是DOI,文献DOI怎么找? 3425651
关于科研通互助平台的介绍 2550861
邀请新用户注册赠送积分活动 2469363